Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz(University of Miami), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Dzhelil Osmanov, Angelo Michele Carella(San Antonio College), Eric L. Sievers(Seagen (United States)), Andy Chi(Takeda (United States)), Andy I. Chen(Scripps Research Institute), Muneer H. Abidi(Spectrum Health), Veronika Bachanová(University of Minnesota), Naomi Hunder(Fred Hutch Cancer Center), John Sweetenham(Cleveland Clinic), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Jerzy Hołowiecki(Medical University of Silesia), Tamás Masszi, Alessandro M. Gianni(University of Milan), Edward Agura(Baylor University), Dirk Huebner(Takeda (United States)), Emily K. Larsen(University of Washington), Auayporn Nademanee(City Of Hope National Medical Center), Patrick J. Stiff(Loyola University Medical Center)
Cited by 740
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
|New England Journal of Medicine|2007|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k